Nizatidine ameliorates gastroparesis in Parkinson's disease: a pilot study.

Abstract

BACKGROUND:

The objective of this work was to perform an open trial of the effects of nizatidine (NZT), a selective histamine H2-receptor antagonist and a cholinomimetic, on gastroparesis in Parkinson's disease (PD) patients, using objective parameters given by a gastric emptying study using a (13) C-sodium acetate expiration breath test.

METHODS:

Twenty patients with PD were enrolled in the study. There were 13 men and 7 women; aged 68.0 ± 7.72 years; disease duration 5.50 ± 3.62 years. All patients underwent the breath test and a gastrointestinal questionnaire before and after 3 months of administration of NZT at 300 mg/day. Statistical analysis was performed by Student t test.

RESULTS:

NZT was well tolerated by all patients and none had abdominal pain or other adverse effects. NZT significantly shortened Tmax ((13) C) (the peak time of the (13) C-dose-excess curve) (P < 0.05).

CONCLUSIONS:

Although this is a pilot study, we found a significant shortening of gastric emptying time after administration of NZT in PD patients.

• Authors: Hirokazu Doi, Ryuji Sakakibara, Mitsutoshi Sato, Shigekazu Hirai, Tohru Masaka, Masahiko Kishi, Yohei Tsuyusaki, Akihiko Tateno, Fuyuki Tateno, Osamu Takahashi, Tsuyoshi Ogata
• Journal: Movement disorders : official journal of the Movement Disorder Society (Mov Disord) Vol. 29 Issue 4 Pg. 562-6 (Apr 2014) ISSN: 1531-8257 [Electronic] United States
• PMID: 24375669 (Publication Type: Journal Article)
• Copyright: © 2013 International Parkinson and Movement Disorder Society.

Chemical References

• Histamine H2 Antagonists
• Nizatidine

Topics

• Aged
• Female
• Gastroparesis (drug therapy, etiology)
• Histamine H2 Antagonists (therapeutic use)
• Humans
• Male
• Middle Aged
• Nizatidine (therapeutic use)
• Parkinson Disease (complications)
• Pilot Projects
• Treatment Outcome